- Business Wire•12 minutes agoBristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Bristol-Myers Squibb Company and Ono Pharmaceutical Company, Ltd. today announced the companies have signed a global patent license agreement with Merck & Co., Inc. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda .
- Investor's Business Daily•1 hour ago
Bristol-Myers Squibb won't seek accelerated approval of Opdivo for lung cancer, giving Merck's Keytruda a bigger head start.
- Bloomberg•2 hours ago
Missteps with its leading cancer drug threaten its lead over Merck.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||48.92 - 50.69|
|52 Week Range||48.92 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.62|
|Dividend & Yield||1.56 (2.78%)|
|1y Target Est||N/A|